Skip to main content

Isracann Enters MOU for European Distribution

Written by admin on . Posted in Public Companies.

VANCOUVER, British Columbia, Jan. 02, 2020 (GLOBE NEWSWIRE) — Isracann Biosciences Inc.  (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) an Israel-based business focused on becoming a premier low cost, high quality cannabis producer for both domestic and European export sales is pleased to announce entry into a Memorandum of Understanding (“MOU”) towards a distribution agreement serving key legalized European cannabis markets.Due to commercial practicalities, the currently unnamed distributor has provisionally agreed to enter an understanding with Isracann towards a strategic export and processing opportunity as part of a pending definitive agreement. The agreement in principal proposes a non-binding option on dried flower product subject to Israeli export laws and defined by minimum quantity, quality and period of delivery.The proposed distributor represents that they will import the product through the Republic of Malta, subject to compliance with jurisdictional importation and transhipment regulations. The distributor asserts its plan to utilize the Isracann product as raw input for value added processing, extraction, packaging, branding and export distribution.As part of the agreement, the distributor further asserts it is preparing a regional processing facility designed to meet European Union Good Manufacturing Practice (EU-GMP) as stipulated by the EU as a regulatory requirement for medicinal products.Mr. Darryl Jones, Isracann’s CEO states, “Well before we began our agricultural efforts in Israel, we recognized the need for strategic distribution agreements. Malta has long been on our radar due to its favourable business environment, excellent logistics and proximity to major European markets. While we continue to build momentum in Israel, we concurrently undertook to identify a potential partner with a similar big picture vision and goals. We believe this agreement can expedite our entry into these markets as purveyors of what we aim to brand as the gold standard of Israel’s cannabis export sector.”Isracann has previously announced that Germany is its stated target for entry into the EU markets pending achievement of Israeli export licensing approval. Germany legalized medical cannabis in March 2017 and today is the largest medical cannabis market in Europe. With a potential patient base of over 1 million patients, it stands to grow substantially over the next several years.“The team here at Isracann believes that beyond Germany, future markets such as Denmark and the United Kingdom are poised to help grow the entire region into an immense opportunity much larger and more sophisticated than currently found in the Americas,” continues Mr. Jones. “Our announcement today is part of our fundamental strategy and marks the beginning of the next chapter in our development. We are excited to begin the decade with new alliances and opportunities ahead.”ON BEHALF OF THE BOARD OF DIRECTORS“Darryl Jones”Darryl Jones
Chief Executive Officer and PresidentAbout Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)The CSE does not accept responsibility for the adequacy or accuracy of this release.All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. Forward looking statements include but are not limited to the achievement of necessary permits for export of cannabis from Israel and to complete its proposed cultivation facilities. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.Contact
Investor Relations
Toll Free: +1 855.205.0226
Email: inquiries@isracann.com
Web:  www.isracann.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.